Mobile Menu

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us
  • Menu
  • Skip to primary navigation
  • Skip to main content

https://eyecro.com

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us

Preclinical Ophthalmic Contract Research

Retinitis Pigmentosa: FDA approves first retinal implant for advanced adult RP

April 2, 2015 //  by stanselb

Retinitis pigmentosa (RP) is a group of inherited disorders characterized by progressive peripheral vision loss and night vision difficulties (nyctalopia) that can lead to central vision loss. The US Food and Drug Administration (FDA) has approved the first retinal implant, the Argus II Retinal Prosthesis System, for adults aged 25 years or older with advanced RP. The implant includes a small video camera, transmitter mounted on a pair of eyeglasses, video processing unit (VPU), and an implanted retinal prosthesis (artificial retina). The VPU transforms images from the video camera into electronic data that are wirelessly transmitted to the retinal prosthesis.

Read the entire article here

Category: NewsTag: dark adaptation, electroretinogram, ERG, fluorescein angiography, macular edema, Retinal detachment, retinitis pigmentosa, visual acuity, visual loss

Previous Post: « Tiny Nanoparticles Could Make Big Impact for Cornea Transplants
Next Post: Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease »

© 2023 · EyeCRO · All Rights Reserved.